Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer

Abstract

Capmatinib showed substantial antitumor activity in patients with advanced NSCLC with a <i>MET</i> exon 14 skipping mutation, particularly in those not treated previously. The efficacy in <i>MET</i>-amplified advanced NSCLC was higher in tumors with a high gene copy number than in those with a low gene copy number. Low-grade peripheral edema and nausea were the main toxic effects. (Funded by Novartis Pharmaceuticals; GEOMETRY mono-1 ClinicalTrials.gov number, NCT02414139.).